bioRxivBioinformaticsPreprint
Transcriptomic Integration Reveals a Conserved Inflammatory--Proliferative Paradox in Acquired Resistance to Immune Checkpoint Blockade
Hoyeon LeeiD, Heerim YeoiD, Inseon Bak, Kyeong-Won YooiD, Sang‐Min ParkiD
Abstract
Acquired resistance to immune checkpoint blockade (ICB) is increasingly recognized as an active adaptive process. However, prior studies have typically focused on individual tumor models, limiting the ability to distinguish conserved mechanisms from model-specific observations. Here, we integrated four independent transcriptomic datasets of acquired ICB resistance, spanning human non-small cell lung cancer (NSCLC) biopsies, murine CT26 colorectal tumors, organoid-derived murine NSCLC tumors, and EMT6 breast cancer cells. Differential expression analysis was performed within each dataset, followed by an intersection-based consensus approach to identify reproducible resistance-associated programs. Contrary to the conventional cold tumor paradigm, acquired-resistance tumors consistently maintained interferon-{gamma} response and innate immune signaling while simultaneously activating cell-cycle programs and constitutive KRAS signaling signatures across all four models. We term this an apparent inflammatory-proliferative paradox: the persistence of IFN-{gamma}-driven inflammatory signatures, canonically associated with productive antitumor immunity, in tumors that have escaped immune control. Notably, this program was retained in immune-depleted organoid and cell-line models, supporting a tumor-cell-associated component maintained independently of the immediate immune microenvironment. Transcription factor activity inference identified a conserved regulatory backbone linking interferon-associated regulators (STAT2, IRF2) with proliferation drivers (E2F4, TFDP1) and suppression of lineage-specifying factors (HNF4A, EGR1). Integrated network analysis resolved these signals into three reinforcing modules, namely hyper-proliferative outgrowth, active inflammatory adaptation, and lineage identity loss. This architecture provides a systems-level framework for prioritizing combination strategies that simultaneously address interconnected resistance axes.
- organism: human
- organism: mouse
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: benchmarking
- approach: statistical model
- approach: matrix factorization
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy
Mohamed Reda Keddar, Sebastian Carrasco Pro, … Martin L. Miller·Journal for ImmunoTherapy of CancerPeer-reviewed·May 1, 2026
- Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
D. Memon, H. Rizvi, … M. D. Hellmann·bioRxiv·Jul 21, 2021
- T cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL-1 and TNFa Inflammation.
N. W. Cho, S. M. Guldberg, … M. H. Spitzer·bioRxiv·Sep 20, 2022
- Multi-compartment immune and tumor cell reprogramming by IFNa2 overcomes colon cancer immunotherapy resistance
Zainab A. Tiamiyu, Patrick Czabala, … Kebin Liu·bioRxiv·Aug 28, 2026
- Targeting Interferon-Driven Inflammatory Memory Prevents Epigenetic Evolution of Cancer Immunotherapy Resistance
Jingya Qiu, Darwin Ye, … Andy J. Minn·bioRxiv·Aug 13, 2024
- Acquired resistance to immune checkpoint inhibitors is associated with hypoxia and ECM remodeling in colorectal cancer
Astrid Zedlitz Johansen, Hannes Linder, … Daniel Hargbøll Madsen·bioRxiv·Apr 29, 2026